Vladislav Mileyko
YOU?
Author Swipe
View article: 67P Multi-institutional evaluation of interrater agreement of biomarker-drug pair rankings based on the ESMO scale for clinical actionability of molecular targets (ESCAT) and sources of discordance
67P Multi-institutional evaluation of interrater agreement of biomarker-drug pair rankings based on the ESMO scale for clinical actionability of molecular targets (ESCAT) and sources of discordance Open
View article: Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experience
Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experience Open
Genomic profiling, or molecular profiling of the tumor, is becoming a key component of therapeutic decision making in clinical oncology, and is typically carried out via next generation sequencing. However, the interpretation of the result…
View article: Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy Open
Colorectal cancer (CRC) is currently one of the most common tumor types diagnosed worldwide. In the early stages, the disease responds well to surgical and chemotherapeutic treatment, but in the later stages when therapeutic options are ex…
View article: 103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience Open
Microsatellite instability (MSI) is a powerful predictor for the efficacy of immune checkpoint inhibitor (ICI) therapy across tumor types. Although conventional MSI testing strategies are widely used, NGS represents a promising tool for MS…
View article: Precision oncology strategy in cetuximab-resistant ERRFI1-mutant colon cancer: case report of disease progression on afatinib.
Precision oncology strategy in cetuximab-resistant ERRFI1-mutant colon cancer: case report of disease progression on afatinib. Open
Despite the existence of effective first and second line therapy options for patients with colorectal cancer, heavily treated patients have limited additional therapies. Genomic profiling is a promising tool for guiding subsequent treatmen…
View article: Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?
Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants? Open
"Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?" published on Feb 2022 by National Comprehensive Cancer Network.
View article: Incidental germline findings during molecular profiling of tumor tissues for precision oncology: molecular survey and methodological obstacles
Incidental germline findings during molecular profiling of tumor tissues for precision oncology: molecular survey and methodological obstacles Open
View article: 13P Incidental germline findings from tumor molecular profiling for precision oncology: Is it common and how to manage?
13P Incidental germline findings from tumor molecular profiling for precision oncology: Is it common and how to manage? Open
View article: Clinical application of routine comprehensive tumour molecular profiling in the management of cancer patients
Clinical application of routine comprehensive tumour molecular profiling in the management of cancer patients Open
View article: Novel bioinformatics quality control metric for next-generation sequencing experiments in the clinical context
Novel bioinformatics quality control metric for next-generation sequencing experiments in the clinical context Open
As the use of next-generation sequencing (NGS) for the Mendelian diseases diagnosis is expanding, the performance of this method has to be improved in order to achieve higher quality. Typically, performance measures are considered to be de…
View article: Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity
Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity Open
Genotyping of cell-free DNA (cfDNA) in plasma samples has the potential to allow for a noninvasive assessment of tumor biology, avoiding the inherent shortcomings of tissue biopsy. Next generation sequencing (NGS), a leading technology for…
View article: Lessons from the routine tumor molecular profiling in Russia
Lessons from the routine tumor molecular profiling in Russia Open
Background: Cost-effectiveness is one of the major limitations for tumor molecular profiling along with a small fraction of patients who can benefit from precision oncology approach. Our experience of providing an affordable molecular prof…
View article: NGS cfDNA data as a basis for the development of qPCR diagnostic systems
NGS cfDNA data as a basis for the development of qPCR diagnostic systems Open
Background: Circulating cell-free DNA (cfDNA) analysis can serve as a powerful diagnostic tool. However, most of the modern techniques used in oncology nowadays are based on expensive NGS procedures on the nuclear DNA. Here we propose a ne…
View article: Design of targeted next-generation sequencing (NGS) of circulating tumour DNA (ctDNA): towards overcoming DNA
Design of targeted next-generation sequencing (NGS) of circulating tumour DNA (ctDNA): towards overcoming DNA Open
View article: Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions
Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions Open
Reporting of entire mutational spectrum revealed by targeted sequencing is questionable, at least until the clinically-driven guidelines on reporting of somatic mutations are established. The standardization of sequencing protocols, especi…
View article: NGS for precision medicine in non-small cell lung cancer: Challenges and opportunities
NGS for precision medicine in non-small cell lung cancer: Challenges and opportunities Open
View article: Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation
Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation Open